Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Correction: Development of highly active anti-Pneumocystis bisbenzamidines: insight into the influence of selected substituents on the in vitro activity

D. Maciejewska *a, J. Żabiński a, M. Rezler a, P. Kaźmierczak a, M. S. Collins bc, L. Ficker bc and M. T. Cushion *bc
aDepartment of Organic Chemistry, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1 Street, 02-097 Warsaw, Poland. E-mail: dmaciejewska@wum.edu.pl
bDivision of Infectious Diseases, Department of Internal Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267, USA. E-mail: cushionmt@ucmail.uc.edu
cCincinnati Veterans Affairs Medical Center, 3200 Vine Street, Cincinnati, OH 45220, USA

Received 30th October 2017 , Accepted 30th October 2017

First published on 7th November 2017


Correction for ‘Development of highly active anti-Pneumocystis bisbenzamidines: insight into the influence of selected substituents on the in vitro activity’ by D. Maciejewska et al., Med. Chem. Commun., 2017, 8, 2003–2011.


The authors regret that on page 7 of their article the name for compound 13 contains an error. The correct name for 13 is: 1,5-bis(4-amidino-2-nitrophenoxy)-3-oxapentane dihydrochloride (with -2- instead of -3-nitrophenoxy).

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.


This journal is © The Royal Society of Chemistry 2017